8-K: Invivyd, Inc. Receives Nasdaq Delisting Notice Due to Low Share Price

Invivyd, Inc. has been notified by Nasdaq that its stock price has fallen below the minimum required for continued listing, triggering a potential delisting process.

Summary

• Invivyd, Inc. received a letter from Nasdaq on December 27, 2024, stating that its stock price had closed below $1.00 per share for 30 consecutive business days.
• This violates Nasdaq's minimum bid price requirement for continued listing on the Nasdaq Global Market.
• Invivyd has 180 calendar days, until June 25, 2025, to regain compliance by having its stock price close at or above $1.00 for at least ten consecutive business days.
• If compliance is not achieved by June 25, 2025, Invivyd may be eligible for an additional 180-day compliance period if it transfers to the Nasdaq Capital Market and meets certain other requirements.
• If the company fails to regain compliance within the allotted time, it may face delisting from Nasdaq, although it can appeal this decision.

Sentiment

Score: 3

Explanation: The document indicates a significant negative event with the potential for delisting, creating a high level of uncertainty and risk for investors.

Positives

• The company has been given 180 days to regain compliance, which provides time to address the issue.
• There is a possibility of an additional 180-day compliance period if the company transfers to the Nasdaq Capital Market.

Negatives

• The company's stock price has fallen below the minimum required for continued listing on the Nasdaq Global Market.
• There is a risk of delisting if the company fails to regain compliance within the given timeframes.
• There is no guarantee that the company will be able to regain compliance with the minimum bid price requirement.

Risks

• The company may not be able to increase its stock price to $1.00 or above for the required ten consecutive business days.
• Nasdaq may not grant the company an additional compliance period.
• The company may ultimately be delisted from the Nasdaq Stock Market.
• The company's appeal of a delisting notice may not be successful.

Future Outlook

The company intends to monitor its stock price and consider options to regain compliance, but there is no guarantee of success. The company's future is uncertain regarding its ability to maintain its Nasdaq listing.

Management Comments

• The company intends to actively monitor the closing bid price for the Common Stock.
• The company will consider implementing available options to resolve the deficiency and regain compliance with the Minimum Bid Price Requirement.

Industry Context

This announcement reflects a common challenge for companies with declining stock prices, particularly in the biotech sector where market sentiment can be volatile. Many companies face similar delisting risks if they cannot maintain minimum listing requirements.

Comparison to Industry Standards

• Many biotech companies, especially those in early stages of development, face similar challenges with maintaining stock prices above minimum listing requirements.
• Companies like Cassava Sciences (SAVA) and Ocugen (OCGN) have faced similar delisting warnings in the past, highlighting the volatility and risk in the biotech sector.
• The 180-day compliance period is a standard procedure for Nasdaq, and the possibility of a second compliance period is also a common practice.

Stakeholder Impact

• Shareholders face the risk of losing their investment if the company is delisted.
• Employees may experience uncertainty about the company's future.
• The company's reputation and ability to attract future investment may be negatively impacted.

Next Steps

• The company will monitor its stock price.
• The company will consider options to regain compliance with Nasdaq listing requirements.
• The company may need to transfer to the Nasdaq Capital Market to gain an additional compliance period.

Key Dates

Keywords

delisting, Nasdaq, minimum bid price, compliance, stock price, IVVD, deficiency letter